R
96.31
-1.02 (-1.05%)
| Previous Close | 97.33 |
| Open | 97.84 |
| Volume | 1,431,551 |
| Avg. Volume (3M) | 3,378,436 |
| Market Cap | 18,618,630,144 |
| Price / Sales | 9.04 |
| Price / Book | 4.58 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -4.01 |
| Total Debt/Equity (MRQ) | 6.46% |
| Current Ratio (MRQ) | 13.46 |
| Operating Cash Flow (TTM) | -591.31 M |
| Levered Free Cash Flow (TTM) | -349.13 M |
| Return on Assets (TTM) | -23.09% |
| Return on Equity (TTM) | -36.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Revolution Medicines, Inc. | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.75 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.02% |
| % Held by Institutions | 105.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 170.00 (Stifel, 76.51%) | Buy |
| Median | 144.00 (49.52%) | |
| Low | 120.00 (Piper Sandler, 24.60%) | Buy |
| Average | 143.78 (49.29%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 108.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 145.00 (50.56%) | Buy | 102.15 |
| Piper Sandler | 26 Feb 2026 | 120.00 (24.60%) | Buy | 102.15 |
| Wells Fargo | 26 Feb 2026 | 144.00 (49.52%) | Buy | 102.15 |
| JP Morgan | 02 Feb 2026 | 122.00 (26.67%) | Buy | 97.16 |
| Oppenheimer | 27 Jan 2026 | 150.00 (55.75%) | Buy | 99.82 |
| Stifel | 22 Jan 2026 | 170.00 (76.51%) | Buy | 118.81 |
| RBC Capital | 21 Jan 2026 | 140.00 (45.36%) | Buy | 117.53 |
| Guggenheim | 20 Jan 2026 | 160.00 (66.13%) | Buy | 116.22 |
| Mizuho | 13 Jan 2026 | 143.00 (48.48%) | Buy | 119.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 |
| 29 Jan 2026 | Announcement | Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor |
| 08 Jan 2026 | Announcement | Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib |
| 05 Jan 2026 | Announcement | Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Announcement | Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |